From the Journals

When to Treat First in Metastatic NSCLC?

Real-world data show flexible sequencing of immunotherapy and local radical treatment can achieve durable survival in selected patients with synchronous oligometastatic NSCLC

Share

A study evaluating treatment sequencing for patients with synchronous oligometastatic non-small cell lung cancer (NSCLC) without actionable genetic alterations shows that both upfront and delayed local radical treatment (LRT) combined with immune checkpoint inhibitors (ICIs) yield a comparable three-year overall survival of approximately 45%. Conducted on patients treated between 2018-2022, this analysis underscores the significance of patient selection over strict adherence to treatment sequences, emphasizing the need for multidisciplinary discussions amidst existing uncertainties.

Original Source(s)

When to Treat First in Metastatic NSCLC?

Real-world data show flexible sequencing of immunotherapy and local radical treatment can achieve durable survival in selected patients with synchronous oligometastatic NSCLC

  • by Jo Cavallo

  • January 13, 2026

  • 5 min

Related Content

Interventional Pulmonology at Atlantic Health, Where Precision Diagnostics Meets Patient-Centered Care

At Morristown and Overlook Medical Centers, robotic bronchoscopy and multidisciplinary collaboration are redefining what’s possible for patients with suspected lung cancer.

  • by

  • September 3, 2025

  • 6 min
Dual Use of E-Cigarettes and Cigarettes Quadruples Lung Cancer Risk, Study Finds

In a First, FDA Approves Flavored E-Cigarettes

'The strength of evidence of benefits to adult smokers from completely switching to a less harmful product was sufficient to outweigh the risks to youth.'